

IN THE CLAIMS**Claims 1-270 (canceled)**

271. **(previously presented)** A method of treating or preventing an ophthalmologic disorder in a subject comprising administering to a subject a pharmaceutically acceptable amount of fenretinide or a pharmaceutically acceptable salt thereof.
272. **(previously presented)** The method of claim 271, wherein fenretinide inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
273. **(previously presented)** The method of claim 271, wherein the ophthalmologic disorder is macular degeneration.
274. **(previously presented)** The method of claim 271, wherein the ophthalmologic disorder is Stargardt's disease.
275. **(previously presented)** The method of claim 271, wherein the ophthalmologic disorder is lipofuscin accumulation.
276. **(previously presented)** The method of claim 271, wherein fenretinide increases the rate at which 11-*cis*-retinal is isomerized to all-*trans*-retinal; inhibits, antagonizes, or short-circuits the visual cycle in the retinal pigment epithelium; inhibits at least one of lecithin retinol acyl transferase, isomerohydrolase, and 11-*cis*-retinol dehydrogenase, or inhibits binding to RPE65.
277. **(previously presented)** The method of claim 271, wherein a second drug different from the first drug is used in the preparation of the medicament.
278. **(previously presented)** The method of claim 277, wherein the second drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
279. **(previously presented)** The method of claim 277, wherein both fenretinide and the second drug inhibit or antagonize a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.